Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
about
Antibody Drug Conjugates: Preclinical ConsiderationsRise and fall of an anti-MUC1 specific antibodyComputational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Using antibodies to target cancer therapeutics.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.Tumour vasculature targeting agents in hybrid/conjugate drugs.Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.Evolving Strategies for Target Selection for Antibody-Drug Conjugates.In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Site-specific chemical modification of antibody fragments using traceless cleavable linkers.An immunohistochemical assay on human tissue using a human primary antibody.The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculatureA Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
P2860
Q27022321-2541653B-311A-4400-934B-FA05ECE48E0FQ28743508-0389E310-EDFA-4146-8F0A-4F35A5F61486Q34663010-E82ECB60-ABD6-42A8-9D25-5555B3144235Q35992488-8D875E77-51C1-4A50-A5E2-497FFB1E5983Q36469716-5999028E-C721-4BF9-8537-E04A09A159EFQ37845396-8A154E10-030E-479D-BF8A-A8E709A2BCDAQ38014920-A1699D38-453E-4E6B-8001-A11412CBE4F7Q38084826-90AA6621-7C26-4248-BF54-6CF6CDCEC8BAQ38094627-6CF50EC7-215D-4F6A-82A1-35CC4FCB0697Q38708078-DEAA18B9-B95C-49E6-B247-3D38D2881677Q38726647-7F6DFAE8-AABB-46A0-8561-46EB57423118Q38842103-7A1B3009-81E2-4D4C-BCF3-01A23CD2B564Q38920359-35431B6C-F49A-4036-9D68-E7DF30E5A572Q39257411-EDEAA703-D757-43F1-A7AB-5F5A6300C392Q39457393-EC2B0DCA-C9B9-4ADC-8D0B-875FFA7D47EEQ41282870-742640FF-4DE6-4BFC-BBC9-94A7CBF76157Q44829143-A6A4E922-044D-4341-8050-A61DFE71DB43Q46957910-2E421D52-1432-4B77-B8DD-8C412DA0A1AEQ51024674-CD029B79-A6DE-4F8C-A54D-85870EB8F2B2Q57911963-9ED5BABA-04D0-412F-A3C1-8DE8F7FE5317Q57911965-3FFABC76-53BB-4320-87F7-4FC16FF526A4
P2860
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@ast
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@en
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@nl
type
label
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@ast
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@en
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@nl
prefLabel
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@ast
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@en
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@nl
P2093
P2860
P356
P1476
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments
@en
P2093
Hans-Peter Gerber
Iqbal S Grewal
Peter D Senter
P2860
P304
P356
10.4161/MABS.1.3.8515
P407
P577
2009-01-01T00:00:00Z